PHARMOSA - Key Persons
Job Titles:
- Associate Director of Research & Department
Ms. Chen obtained a Ph.D. from the Department of Chemical Engineering at National Tsinghua University, specializing in the research and design of dosage pharmaceuticals. She previously worked in Taiwan Liposome Company as a researcher for developing dosage pharmaceuticals, during which she participated in the research and development of new anti-cancer drugs. At Pharmosa Biopharm, Ms. Chen was mainly responsible for the development of combination products for trial drugs and medical devices, as well as the management of relevant patents. Ms. Chen currently has obtained more than 10 domestic and foreign patents, and also has experience in analytical methods, development of mass production processes, and CMO technology transfer.
Dr. Han received her bachelor degree in Veterinary Medicine from Taiwan University and master degree and doctorate from The University of Tokyo (Japan). She was a Director of the Taiwan Liposomal Company, Study Director in preclinical toxicology division of Green Season Biotech Co. (Taiwan), Visiting Scholar at The University of Tokyo (Japan), Study Director/Research Fellow at Research Institute for Animal Science in Biochemistry & Toxicology (RIAS) (Japan), and Veterinary Researcher in Central Experimental Institute of Liberia (West Africa), and Veterinary Officer in Ministry of Agriculture of Liberia (West Africa). She has more than 3 decades of experiences in preclinical experiments, running general toxicity studies, reproduction/ developmental toxicity study, pharmacokinetic/toxicokinetic studies, setting up/efficacy valuation for animal disease models etc., as well as preparation of IND/ANDA documents for submission. Additionally, she was a team member for animal toxicology studies in "High Production Volume Chemicals Assessment Programme "which was advocated by OECD at 90". She is now a consultant of Pharmosa in terms of preclinical experiments.
Dr. Narang received his M.S. in Pharmaceutics from West Virginia University, and a Ph.D. in Pharmacokinetics from University of Maryland. He started his career at US National Institutes of Health after graduation. His career paths included leadership roles at Novartis, Pharmacia, GE (Medical Diagnostics), as well as Dr. Reddy's (Biologics) in Regulatory, Quality, and Pharmacovigilance domains. Before expanding into the field of regulatory, Dr. Narang was the US Head of the Clinical Pharmacology/Pharmacokinetics group for Pharmacia. Most recently, he served as the VP of Scientific & Regulatory Strategy for a business focusing on leveraging 505(b)(2) NDA pathway. Dr. Narang brings more than 35 years of industrial experiences, not only in the scientific areas, but also in the global perspective with regulatory insights and scientific rigor into business decisions, R&D operations, and across development, marketing authorization, and brand protection. Dr. Narang is now the president of P.K. Narang Strategic Consulting providing advisory practices for life-science industry. He also serves in Advisory Board for several start-ups.
Job Titles:
- Senior Director of Research & Department
Dr. Liang graduated from the Chemical Engineer Department of National Tsinghua University in Taiwan in 2005. Before joining Pharmosa, he served as Senior Director of the Manufacturing & Technology Division of TaiMed Biologics and as Senior Researcher of Industrial Technology Research Institute. When he worked in TaiMed, he was responsible for the tech transfer, process development and scale-up, GMP manufacturing, and CMC package preparation and submission of nanomedicine and antibody drugs. He participated in the development and commercialization of the first anti-HIV antibody in the US and EU as well as the regulatory submission of post-approval changes and the manufacturing site change. He also took charge of the developmental strategies of products in different stages of clinical trials.
Job Titles:
- Vice President of Operations
Mr. Pao has over 30 years of experience in pharmaceutical manufacturing operations and supply chain management. Prior to joining Pharmosa, he served for Taiwan Liposome Company (TLC) and held positions as manufacturing development senior director, where he was responsible for outsourcing management, CMC operations, manufacturing transfer and purchasing activities. Before the Taiwan Liposome Company, Mr. Pao served for Taiwan Yamanouchi Pharmaceutical (now Astellas Pharma). During his time with Yamanouchi, Mr. Pao held various positions including technical services, QA/QC manager, responsible for validation activities and GMP plant management. After that he served as a manager of regulatory affairs in charge of drug registration. Mr. Pao holds a bachelor degree from the Department of Pharmacy, Chia Nan University of Pharmacy & Science. He also has a pharmacist certificate.
Job Titles:
- Master of Medical Technology
Job Titles:
- Vice President of Administrations
Ms. Lin received an MBA degree from University of California, Riverside, USA. Ms. Lin has more than 3 decades of experiences in management and administration for start-ups, bio-tech and public companies covering corporate governance and compliances, ESG, HR, international contracts, taxation, fund raising, strategic cross-border subsidiaries setups, organizational behaviors, etc. Prior to joining Pharmosa, she served as VP of Administration in TLC for more than 15 years, from pre-IPO to public stages. She also worked in California-based technology firms and CPA firm in earlier years of career. Ms. Lin is recognized as a Certified Public Accountant in California, USA.
Dr. Kan graduated from National Tsinghua University in Taiwan and completed post-doctoral research at Tsukuba University in Japan. He served as Associate Director of the Taiwan Liposomal Company, a Researcher at the Biomedical Engineering Center of the Industrial Technology Research Institute, and a Researcher at Tsukuba University in Japan. He has worked in the pharmaceutical industry for more than 20 years, focused on pharmaceutical formulation technology and product development, published over 50 papers and more than 10 patents related to drug delivery, some of which have been used in clinical products. In addition, he has led the development of several new formulation-based drug projects and completed filing and listing of IND, BioIND, and ANDA products in Taiwan, China, the United States, Japan, and Europe. He is now the President of Pharmosa.
Job Titles:
- Associate Director of Strategies & Project Development
Ms. Chuang was graduated from the Traditional Medicine Institute at Yang Ming Chiao Tung University. Her expertise lies in clinical trial planning and execution, CRO selection and project management. With over 15 years of experience in clinical relevant positions at international pharmaceutical companies, biotech companies, and CROs. She was responsible for project management and execution in Phase I-IV clinical trials, including clinical trial strategy development and planning across various therapeutic areas, CRO management, and participation in IRB audits and TFDA inspections. She also had experiences in conducting clinical trials with combination products. Currently, she serves as the Associate Director at Pharmosa, leading the key products into Phase III clinical trials, planning clinical development on new indications, and strategizing, planning, managing, and executing international clinical trials.She was a Clinical Manager at BioGend Therapeutics Co., Ltd., Clinical Project Manager at Taiwan Liposome Company, Ltd., and Clinical Manager at Novartis Taiwan Co., Ltd.
Job Titles:
- Senior Director of Strategies & Project Development
Mr. Lu holds a master's degree from the Department of Pharmacology and Toxicology, Tzu Chi University and has over 15 years' experience in new drug development. Mr. Lu was Vice President of Product Development in TWi Biotechnology, Inc. In the role of Vice President, Mr. Lu managed TWi leading project development programs in the areas of rare disease and skin inflammatory disorders, managed and accomplished IND filings, orphan drug designation approval from US FDA/TFDA and patent application. He also has a pharmacist certificate.
Current Position:
Director of the Board of Directors of Taipei Medical University
Chair Professor of the Graduate Institute of Medical Sciences at Taipei Medical University
Honorary Distinguished Lecture at National Chengkung University
Academician of Academia Sinica
Committee Member of Salary and Compensation Committee of Universal Cement Corporation
Independent Director of ScinoPharm Taiwan, Ltd.
Independent Director of Taiwan Aulisa Medical Devices Technologies, Inc.
Experiences:
Chairman of the Board of Directors of Taipei Medical University
Director of the Biological Sciences Development Division of the National Science Council of the Executive Yuan
Vice Chairman of the Institute for Biotechnology and Medicine Industry
Professor of the Department of Pharmacology, and Director of the Institute of Basic Medical Sciences under the Department of Pharmacology at the National Cheng Kung University College of Medicine;
Associate Dean of the College of Medicine, Chair Professor, Director of the University Center for Bioscience and Biotechnology, Dean of the College of Bioscience and Biotechnology, Honorary Distinguished Lecturer
Education:
PhD, Graduate School of Pharmaceutical Sciences, Faculty of Pharmacy, University of Tokyo
Master of Pharmacy, Faculty of Pharmacy, University of Tokyo
Bachelor of Pharmacy, Taipei Medical College (Now Taipei Medical University)
Job Titles:
- Director / Legal Representative of: Fukeshen Investment Co., Ltd
Job Titles:
- Vice President of Finance & Accounting
Ms. Yang graduated from the Department of Accountancy and the Graduate Institute of Finance from National Cheng Kung University. She brings Pharmosa 15 years of experience in financial and accounting, capital market fundraising and M&A. Prior to joining Pharmosa, Ms. Yang was Senior Vice President of the Investment Banking Department at KGI Securities Co. Ltd. and led 12 IPO projects, 14 SPO projects, 7 M&A projects, and pre-IPO consultation. She also participated in TaiGen Biotech's (TPEx: 4157) US$1.1 billion initial public offering on the Taipei Exchange. Ms. Yang has expertise in investment structure planning, joint ventures, corporate reorganization, corporate governance, auditing and internal control, personnel optimization, business development, and strategic planning. Ms. Yang started her career with KPMG as a financial auditor.
Current Position:
Chief Executive Officer of Peace & Grace International Attorneys at Law
Experiences:
Certified Public Accountant, Certified Public Accountant, Accountant in Charge, Executive Director, and Vice Chairman of the Audit Department of KPMG in Taiwan
Education:
PhD in Finance, Xiamen University
Master of Business Administration, National Chengchi University
Bachelor of Shipping Management, National Taiwan Ocean University